Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient

2024; Springer Nature; Volume: 32; Issue: 3 Linguagem: Inglês

10.1007/s10787-024-01475-2

ISSN

1568-5608

Autores

Rosa María García-Álvarez, Maruxa Zapata‐Cachafeiro, Irene Visos‐Varela, Almudena Rodríguez-Fernández, Samuel Pintos‐Rodríguez, María Piñeiro‐Lamas, María Teresa Herdeiro, Adolfo Figueiras, Ángel Salgado‐Barreira, Rosendo Bugarín González, Eduardo Carracedo‐Martínez, Francisco Javier González‐Barcala, Martina Lema-Oreiro, Narmeen Mallah, Manuel Portela‐Romero, Ángela Prieto-Campo, Marc Sáez, Margarita Taracido,

Tópico(s)

Long-Term Effects of COVID-19

Resumo

To assess the impact of prior chronic treatment with angiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin-receptor blockers (ARBs), both as a group and by active ingredient, on severity (risk of hospitalization and mortality), progression of and susceptibility to COVID-19.

Referência(s)